Review of the Management of Relapsed Small-Cell Lung Cancer with Amrubicin Hydrochloride
Lung cancer is the leading cause of cancer death, and approximately 15% of all lung cancer patients have small-cell lung cancer (SCLC). Although second-line chemotherapy can produce tumor regression, the prognosis is poor. Amrubicin hydrochloride (AMR) is a synthetic anthracycline anticancer agent a...
| Main Authors: | , , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Libertas Academica
2011
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3076041/ |